SUPERNUS PHARMACEUTICALS, INC.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

Supernus Pharmaceuticals, Inc.는 미국 내에서 중추신경계(CNS) 질환 치료용 제품의 개발 및 상업화에 주력하는 바이오 제약 회사입니다. 이 회사는 주의력결핍 과잉행동장애(ADHD) 치료에 사용되는 비자극제 Qelbree; 파킨슨병(PD) 환자의 이상운동증 치료제 GOCOVRI; 부분 발작 간질의 단독 요법 치료에 사용되는 서방형 옥스카르바제핀 제품 Oxtellar XR; 그리고 진행성 파킨슨병(PD) 환자의 운동저하 또는 '오프(off)' 에피소드의 급성 및 간헐적 치료를 위한 APOKYN을 제공합니다. 또한, 간질 치료 및 편두통 예방에 사용되는 서방형 토피라메이트 제품 Trokendi XR; 레보도파/카르비도파 투여 중 '오프(off)' 에피소드를 겪는 파킨슨병(PD) 환자 치료를 위한 XADAGO; 그리고 경부 근긴장이상 및 만성 타액분비과다증 치료에 사용되는 B형 독소 제품 MYOBLOC을 제공합니다. 이